Athira Pharma Inc (nasdaq:ATHA) Share Price

Company Profile

Business description
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Contact
18706 North Creek Parkway
Suite 104
BothellWA98011
USA
T: +1 425 620-8501
E: [email protected]
https://www.athira.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
26

Recommended

SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.

Joseph Taylor | 16 September 2025

Working to prevent repeated failures could also improve competitiveness.

Nathan Zaia | 15 September 2025

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.

Roy Van Keulen | 15 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,094.90	27.60	-0.30%
CAC 40	7,786.98	31.24	-0.40%
DAX 40	23,359.18	29.94	0.13%
Dow JONES (US)	45,984.36	226.46	0.49%
FTSE 100	9,208.37	12.71	0.14%
HKSE	26,908.39	469.88	1.78%
NASDAQ	22,243.38	90.57	-0.41%
Nikkei 225	44,790.38	111.89	-0.25%
NZX 50 Index	13,228.38	6.51	-0.05%
S&P 500	6,595.65	11.11	-0.17%
S&P/ASX 200	8,818.50	30.00	-0.34%
SSE Composite Index	3,876.34	14.48	0.37%